13 October 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointment of Independent Non-Executive Director

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect.

Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategies delivering consistent upper quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes,

Ketan is a CFA Charterholder. He also holds an MSc Economic History, from London School of Economics, MSc Geography from King's College London and BA (Hons) History and Geography from Queen Mary University, London.

Tim McCarthy, Chief Executive Officer of ImmuPharma, said:

"We are extremely pleased to welcome Ketan to our Board. His extensive expertise in the global pharmaceutical and life science sectors and strong investment acumen will be invaluable to ImmuPharma.

Importantly, Ketan's appointment, at this time, brings a unique perspective to the Board, as we concentrate on future strategic partnerships and commercial deals across our product portfolio and in particular, our lead auto-immune platform technology, P140. In addition, Ketan's investment management experience will greatly assist us in expanding our institutional shareholder base."

Ketan Patel, commented:

"After nearly three decades of investing in mid and small cap UK companies with a focus on healthcare and life science, I am delighted to be joining the ImmuPharma team at this pivotal stage of their journey and look forward to contributing to the future success of the business."

Additional information:

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Ketan Ratna Kanji Patel, aged 52, holds or has previously held the following directorships:

Ketan Patel holds no shares in the Company.

Save for the information above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.